Syros Historical Income Statement

SYRS Stock

USD 0.27 0 1.11%

Historical analysis of Syros Pharmaceuticals income statement accounts such as Gross Profit of 7 M, Other Operating Expenses of 87.4 M, Research Development of 68.1 M or Cost Of Revenue of 2.1 M can show how well Syros Pharmaceuticals performed in making a profits. Evaluating Syros Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Syros Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Syros Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Syros Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

About Syros Income Statement Analysis

Syros Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Syros Pharmaceuticals shareholders. The income statement also shows Syros investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Syros Pharmaceuticals Income Statement Chart

At this time, Syros Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 2.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Reconciled Depreciation

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Syros Pharmaceuticals. It is also known as Syros Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Syros Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Syros Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.At this time, Syros Pharmaceuticals' Interest Expense is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 2.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 18.9 M in 2024.

Syros Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Non Operating Income Net Other	Reconciled Depreciation	Net Interest Income	Interest Income
Depreciation And Amortization		0.95	0.81	0.8	0.93	-0.89	-0.77	-0.77	0.92	-0.76	-0.05	0.93	-0.77	0.12	-0.7	0.6	0.91	-0.02	0.3
Selling General Administrative	0.95		0.76	0.71	0.99	-0.96	-0.86	-0.87	0.98	-0.86	-0.07	0.99	-0.86	0.03	-0.78	0.72	0.83	0.16	0.48
Total Revenue	0.81	0.76		0.99	0.83	-0.75	-0.61	-0.6	0.85	-0.59	-0.25	0.83	-0.61	0.19	-0.55	0.7	0.86	-0.21	0.24
Gross Profit	0.8	0.71	0.99		0.78	-0.69	-0.56	-0.55	0.8	-0.54	-0.23	0.78	-0.56	0.19	-0.52	0.64	0.85	-0.26	0.18
Other Operating Expenses	0.93	0.99	0.83	0.78		-0.97	-0.86	-0.86	1.0	-0.85	-0.1	1.0	-0.86	0.04	-0.77	0.79	0.84	0.13	0.5
Operating Income	-0.89	-0.96	-0.75	-0.69	-0.97		0.94	0.93	-0.96	0.93	0.1	-0.97	0.94	0.08	0.84	-0.85	-0.82	-0.31	-0.66
Net Income From Continuing Ops	-0.77	-0.86	-0.61	-0.56	-0.86	0.94		1.0	-0.85	1.0	0.1	-0.86	1.0	0.43	0.97	-0.84	-0.7	-0.57	-0.83
Ebit	-0.77	-0.87	-0.6	-0.55	-0.86	0.93	1.0		-0.85	1.0	0.09	-0.86	1.0	0.43	0.97	-0.82	-0.69	-0.57	-0.82
Research Development	0.92	0.98	0.85	0.8	1.0	-0.96	-0.85	-0.85		-0.84	-0.1	1.0	-0.85	0.05	-0.76	0.8	0.84	0.11	0.5
Ebitda	-0.76	-0.86	-0.59	-0.54	-0.85	0.93	1.0	1.0	-0.84		0.09	-0.85	1.0	0.44	0.97	-0.83	-0.69	-0.58	-0.83
Cost Of Revenue	-0.05	-0.07	-0.25	-0.23	-0.1	0.1	0.1	0.09	-0.1	0.09		-0.1	0.1	0.04	0.08	-0.25	-0.32	-0.08	-0.19
Total Operating Expenses	0.93	0.99	0.83	0.78	1.0	-0.97	-0.86	-0.86	1.0	-0.85	-0.1		-0.86	0.04	-0.77	0.79	0.84	0.13	0.5
Income Before Tax	-0.77	-0.86	-0.61	-0.56	-0.86	0.94	1.0	1.0	-0.85	1.0	0.1	-0.86		0.43	0.97	-0.84	-0.7	-0.57	-0.83
Total Other Income Expense Net	0.12	0.03	0.19	0.19	0.04	0.08	0.43	0.43	0.05	0.44	0.04	0.04	0.43		0.58	-0.2	0.12	-0.83	-0.67
Net Income	-0.7	-0.78	-0.55	-0.52	-0.77	0.84	0.97	0.97	-0.76	0.97	0.08	-0.77	0.97	0.58		-0.76	-0.63	-0.6	-0.81
Non Operating Income Net Other	0.6	0.72	0.7	0.64	0.79	-0.85	-0.84	-0.82	0.8	-0.83	-0.25	0.79	-0.84	-0.2	-0.76		0.65	0.35	0.78
Reconciled Depreciation	0.91	0.83	0.86	0.85	0.84	-0.82	-0.7	-0.69	0.84	-0.69	-0.32	0.84	-0.7	0.12	-0.63	0.65		-0.02	0.33
Net Interest Income	-0.02	0.16	-0.21	-0.26	0.13	-0.31	-0.57	-0.57	0.11	-0.58	-0.08	0.13	-0.57	-0.83	-0.6	0.35	-0.02		0.86
Interest Income	0.3	0.48	0.24	0.18	0.5	-0.66	-0.83	-0.82	0.5	-0.83	-0.19	0.5	-0.83	-0.67	-0.81	0.78	0.33	0.86

Click cells to compare fundamentals

Syros Pharmaceuticals Account Relationship Matchups

Syros Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.7M	3.0M	3.0M	3.0M	2.3M	2.1M
Selling General Administrative	21.5M	21.3M	23.0M	29.3M	28.3M	18.9M
Total Revenue	2.0M	15.1M	23.5M	14.9M	9.9M	7.6M
Gross Profit	2.0M	15.1M	23.5M	11.9M	7.7M	7.0M
Other Operating Expenses	79.7M	97.4M	122.9M	141.2M	138.9M	87.4M
Operating Income	(77.7M)	(82.3M)	(99.4M)	(135.9M)	(129.0M)	(122.5M)
Net Income From Continuing Ops	(75.4M)	(84.0M)	(86.6M)	(94.7M)	(164.6M)	(156.3M)
Ebit	(77.7M)	(82.2M)	(82.7M)	(90.5M)	(159.4M)	(151.5M)
Research Development	58.2M	76.1M	99.9M	111.9M	108.2M	68.1M
Ebitda	(75.0M)	(79.2M)	(79.6M)	(87.6M)	(157.2M)	(149.3M)
Total Operating Expenses	79.7M	97.4M	122.9M	141.2M	138.9M	87.4M
Income Before Tax	(75.4M)	(84.0M)	(86.6M)	(94.7M)	(164.6M)	(156.3M)
Total Other Income Expense Net	2.3M	(1.7M)	12.9M	41.2M	(35.6M)	(33.8M)
Net Income Applicable To Common Shares	(75.4M)	(84.0M)	(86.6M)	(94.7M)	(85.2M)	(89.4M)
Net Income	(75.4M)	(85.8M)	(90.5M)	(49.3M)	(164.6M)	(156.3M)
Income Tax Expense	(2.3M)	1.8M	3.9M	(45.4M)	2.1M	2.2M
Non Operating Income Net Other	2.0M	2.3M	51K	45.4M	52.2M	54.8M
Reconciled Depreciation	2.7M	3.0M	3.0M	3.0M	2.3M	2.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syros Historical Income Statement

About Syros Income Statement Analysis

Syros Pharmaceuticals Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Syros Pharmaceuticals income statement Correlations

Syros Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Syros Pharmaceuticals income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Syros Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Net Income From Continuing Ops
Ebit	Research Development
Ebitda	Cost Of Revenue
Total Operating Expenses	Income Before Tax
Total Other Income Expense Net	Net Income Applicable To Common Shares
Net Income	Income Tax Expense
Preferred Stock And Other Adjustments	Non Operating Income Net Other
Reconciled Depreciation	Net Interest Income
Interest Income

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Net Income From Continuing Ops
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit

Total Operating Expenses	- 0.97	Operating Income
Operating Income	- 0.97	Other Operating Expenses
Research Development	- 0.96	Operating Income
Operating Income	- 0.96	Selling General Administrative
Operating Income	- 0.89	Depreciation And Amortization
Ebit	- 0.87	Selling General Administrative